pembrolizumab + gemcitabine + cisplatin

Pembrolizumab + gemcitabine + cisplatin is a combination regimen used for the treatment of locally advanced unresectable or metastatic biliary tract cancer. Pembrolizumab is a monoclonal antibody immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor, thereby enhancing T-cell mediated anti-tumor responses. Gemcitabine and cisplatin are cytotoxic chemotherapy agents; gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin forms DNA crosslinks leading to apoptosis. The combination was approved based on phase 3 clinical trial data (KEYNOTE-966), which demonstrated improved overall survival compared to chemotherapy alone in this patient population[2][4][5]. Pembrolizumab was developed by Merck.

Brand names

Keytruda + cisplatin + gemcitabine

Other names

pembrolizumab + gemcitabine + cisplatin